Neurogait
Using AI to screen Curable Dementia and other Neurological disease
Company Overview
Snapshot
Founded in July 2019 by Eyal Fruchtman and Ben Francke, Neurogait operates with 1–10 employees. The company has secured funding across one disclosed round from one investor. Neurogait is currently conducting clinical pilots in Germany and integrating its solution under a commercial agreement with a large online European patient platform.
Business overview
Neurogait is a Health Tech & Life Sciences company developing AI-based clinical screenings for neurodegenerative diseases, including curable dementia and Parkinson's. The company's core technology leverages deep learning, computer vision, and machine learning to create diagnostic solutions. Neurogait serves the healthcare and medical devices industries, targeting providers and patients in markets across North America, Europe, and Asia.
Strategic signal
In January 2022, Neurogait was featured for its development of an AI-based ecosystem for neurological disease. This highlights the company's strategic focus on leveraging artificial intelligence and machine learning to create advanced diagnostic tools, signaling its potential to innovate within the digital healthcare and medical technologies sector.
Log in to access full profile ›Company Intelligence Q&A
- When was Neurogait founded and by whom?
- Neurogait was founded in July 2019 by co-founders Eyal Fruchtman and Ben Francke.
- What is Neurogait's primary focus?
- Neurogait focuses on developing AI-based clinical screenings for neurodegenerative diseases, including curable dementia and Parkinson's.
- What is the status of Neurogait's clinical pilots?
- Neurogait is currently conducting clinical pilots in Germany and is integrating its solution under a commercial agreement with a large online European patient platform.
- Which markets does Neurogait target?
- Neurogait targets geomarkets in North America, Europe, and Asia.
- What is Neurogait's current product stage and what does it entail?
- Neurogait's product is currently in the Beta stage, which means it is undergoing testing and refinement before its full commercial release. The company is actively working on regulatory approvals for its solution.